A Familiar Face in the Treatment of Immunoglobulin A Vasculitis: Colchicine
Turkish Journal of Pediatric Disease · 21.01.2025 · 19 (1) · 38-42
DOI: 10.12956/tchd.1514723 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Pediatric Disease, online erschienen am 21.01.2025. Verfasst von Merve Cansu Polat und 12 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The aim of the this study was to evaluate immunoglobulin A vasculitis (IgAV) patients on colchicine therapy and determine the causative factors leading to the initiation and maintenance of colchicine. Material and Methods: This retrospective study was conducted receiving IgAV patients on colchicine at our clinic between January 2013 and June 2023. Demographic, clinical, and laboratory data of IgAV patients were obtained from their electronic medical records.
Results
A total of 33 IgAV patients receiving colchicine, 20 (60.6%) males and 13 (39.4%) females, were included in the study. The mean age at diagnosis of IgAV was 111.6±45.5 months. Colchicine was initiated in 13 (39.4%) patients with persistent rash, 8 (24.2%) with severe gastrointestinal tract involvement, seven (21.2%) with generalized/severe rash, and five (15.2%) with recurrent IgAV. The median elapsed time to colchicine initiation was 30 (10.5-60) days. The median duration of colchicine usage was ten (IQR, 6-54) months. Colchicine treatment was discontinued in 14 patients after a median 6.5 (IQR, 3-11.2) months. At the last visit, 13 (39.4%) patients were receiving colchicine for familial Mediterranean fever (FMF), four (12.1%) for recurrent IgAV, and two (6.1%) for persistent rash.
Conclusion
Colchicine should be kept in mind especially in the presence of severe, persistent or recurrent rash. Early initiation of colchicine treatment should be considered in IgAV patients with severe GI tract disease, especially in countries where FMF is common.
Zitieren
APA
Polat, M. C., Ekici, M. I., Ekici, M. I., Çelikel, E., Tekin, Z. E., Güngörer, V., Karagöl, C., Öner, N., Öztürk, D., Özçelik, E., Es, Y. U., Yoğun, S. N., & Acar, B. (2025). A Familiar Face in the Treatment of Immunoglobulin A Vasculitis: Colchicine. Turkish Journal of Pediatric Disease, 19(1), 38-42. https://doi.org/10.12956/tchd.1514723
Vancouver
Polat MC, Ekici MI, Ekici MI, Çelikel E, Tekin ZE, Güngörer V, et al. A Familiar Face in the Treatment of Immunoglobulin A Vasculitis: Colchicine. Turkish Journal of Pediatric Disease. 2025;19(1):38-42. doi:10.12956/tchd.1514723
BibTeX
@article{Polat2025,
author = {Polat, Merve Cansu and Ekici, Mehveş Işıklar and Ekici, Mehveş Işıklar and Çelikel, Elif and Tekin, Zahide Ekici and Güngörer, Vildan and Karagöl, Cüneyt and Öner, Nimet and Öztürk, Didem and Özçelik, Emine and Es, Yasemin Uğur and Yoğun, Sultan Nilay and Acar, Banu},
title = {A Familiar Face in the Treatment of Immunoglobulin A Vasculitis: Colchicine},
journal = {Turkish Journal of Pediatric Disease},
year = {2025},
volume = {19},
number = {1},
pages = {38--42},
doi = {10.12956/tchd.1514723}
}
EUVIMED